{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% CI was not evaluable due to the high censoring rate.","groupId":"OG000","lowerLimit":"25.74","upperLimit":"NA","value":"27.39"},{"groupId":"OG001","lowerLimit":"11.21","upperLimit":"22.19","value":"17.46"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"150 mg Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG000","title":"Abemaciclib + NSAI"},{"description":"Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG001","title":"Placebo + NSAI"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who had evaluable data. Censored participants: Abemaciclib + NSAI = 112 and Placebo + NSAI =28.","reportingStatus":"POSTED","timeFrame":"CR or PR to Disease Progression or Death Due to Any Cause (Up to 32 Months)","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}